AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is conducting a Phase III study titled ‘ZENITH High Proteinuria’ to evaluate the efficacy, safety, and tolerability of a combination treatment of Zibotentan and Dapagliflozin compared to Dapagliflozin alone in patients with chronic kidney disease (CKD) and high proteinuria. This study aims to provide insights into more effective treatments for CKD, a condition with significant health implications.
The study tests two interventions: a combination drug Zibotentan/Dapagliflozin and Dapagliflozin alone. Zibotentan/Dapagliflozin is administered in fixed doses based on eGFR values, while Dapagliflozin is given as a daily oral dose.
The study is interventional, randomized, and employs a parallel assignment model with quadruple masking (blinding participants, care providers, investigators, and outcomes assessors) to ensure unbiased results. The primary purpose is treatment-focused.
The study began on November 7, 2023, with the last update submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
This study’s update could influence AstraZeneca’s stock performance positively by showcasing its commitment to advancing CKD treatments. It may also affect investor sentiment, especially if the results indicate a competitive edge over similar treatments in the market.
The study is ongoing, with further details available on the ClinicalTrials portal.